Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C14H12N6O |
| Molecular Weight | 280.2847 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1CC(=O)NN=C1C2=CC=C(NN=C(C#N)C#N)C=C2
InChI
InChIKey=WHXMKTBCFHIYNQ-UHFFFAOYSA-N
InChI=1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Levosimendan. | 2001 |
|
| Levosimendan: a new dual-action drug in the treatment of acute heart failure. | 2003 Jun |
|
| The use of the novel calcium sensitizer levosimendan in critically ill patients. | 2004 Aug |
|
| Treatment of acute heart failure in an infant after cardiac surgery using levosimendan. | 2004 Jul |
|
| Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. | 2004 Nov |
|
| Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. | 2005 Dec |
|
| Pharmacology of new agents for acute heart failure syndromes. | 2005 Sep 19 |
|
| Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. | 2007 Apr |
|
| Right ventricular dysfunction. | 2007 Oct |
|
| The protective effects of levosimendan on ischemia/reperfusion injury and apoptosis. | 2011 Jan |
|
| Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. | 2013 Dec |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C78322
Created by
admin on Sat Dec 16 16:19:46 GMT 2023 , Edited by admin on Sat Dec 16 16:19:46 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL313136
Created by
admin on Sat Dec 16 16:19:46 GMT 2023 , Edited by admin on Sat Dec 16 16:19:46 GMT 2023
|
PRIMARY | |||
|
DB12286
Created by
admin on Sat Dec 16 16:19:46 GMT 2023 , Edited by admin on Sat Dec 16 16:19:46 GMT 2023
|
PRIMARY | |||
|
DTXSID20861357
Created by
admin on Sat Dec 16 16:19:46 GMT 2023 , Edited by admin on Sat Dec 16 16:19:46 GMT 2023
|
PRIMARY | |||
|
349552KRHK
Created by
admin on Sat Dec 16 16:19:46 GMT 2023 , Edited by admin on Sat Dec 16 16:19:46 GMT 2023
|
PRIMARY | |||
|
100000083534
Created by
admin on Sat Dec 16 16:19:46 GMT 2023 , Edited by admin on Sat Dec 16 16:19:46 GMT 2023
|
PRIMARY | |||
|
157968-98-4
Created by
admin on Sat Dec 16 16:19:46 GMT 2023 , Edited by admin on Sat Dec 16 16:19:46 GMT 2023
|
SUPERSEDED | |||
|
C076731
Created by
admin on Sat Dec 16 16:19:46 GMT 2023 , Edited by admin on Sat Dec 16 16:19:46 GMT 2023
|
PRIMARY | |||
|
6898
Created by
admin on Sat Dec 16 16:19:46 GMT 2023 , Edited by admin on Sat Dec 16 16:19:46 GMT 2023
|
PRIMARY | |||
|
131741-08-7
Created by
admin on Sat Dec 16 16:19:46 GMT 2023 , Edited by admin on Sat Dec 16 16:19:46 GMT 2023
|
PRIMARY | |||
|
60867
Created by
admin on Sat Dec 16 16:19:46 GMT 2023 , Edited by admin on Sat Dec 16 16:19:46 GMT 2023
|
PRIMARY | |||
|
C87689
Created by
admin on Sat Dec 16 16:19:46 GMT 2023 , Edited by admin on Sat Dec 16 16:19:46 GMT 2023
|
PRIMARY | |||
|
SUB10525MIG
Created by
admin on Sat Dec 16 16:19:46 GMT 2023 , Edited by admin on Sat Dec 16 16:19:46 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
